53 results about "Ischemic brain injury" patented technology

The invention relates to hydrogel for treating ischemic brain injury and a preparation method thereof. The hydrogel is prepared from the following raw materials: methylacryloylated hyaluronic acid, methylacryloylated gelatin, curcumin loaded HA-PPS (Hydroxypropyl-Polyphenylene Sulfite) nano-micelles and dendrobium polysaccharide loaded sodium alginate microspheres. Through combination of a nanotechnology and an intelligent response material, HA-PPS is adopted to load curcumin and sodium alginate microspheres are adopted to encapsulate dendrobium polysaccharide, so that the drug activity can be more effectively protected, the drug is protected to penetrate through a blood brain barrier and be accurately delivered to a brain injury area, and targeted release of the drug is realized; the anti-oxidation and anti-inflammatory effects are better under the combined action of the curcumin and the dendrobium polysaccharides, and meanwhile, a slow release function is also achieved.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a targeted liposome as an active component in preparation of a medicine for treating ischemic brain injury. The targeted lipidosome for treating cerebral arterial thrombosis is prepared by fusing the lipidosome and the platelet-neutrophil aggregate membrane, realizes efficient and specific targeting of an ischemic brain region, effectively reduces brain tissue infarction and damage of a new region, relieves brain inflammation through multi-channel regulation and control, and improves the cerebral arterial thrombosis treatment effect. The compound can be used as an active ingredient for preparing a medicine for treating ischemic brain injury. And after the target liposome is further coated with a rutin drug, the synergistic treatment effect is realized. The liposome medicine can be used as an active component and has a good application prospect in treatment of ischemic brain injury diseases.

To provide 2-aminopyridine derivative compounds for use as inhibitors of nitric oxide synthase.SOLUTION: Disclosed are 2-aminopyridine derivative compounds for use as inhibitors of nitric oxide synthase (NOS). In particular, the field of the present invention relates to 2-aminopyridine derivative compounds for use as inhibitors of neuronal nitric oxide synthase (nNOS), which are formulated as pharmaceutical compositions for treating nNOS-associated diseases and disorders such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, as well as amyotrophic lateral sclerosis, cerebral palsy, stroke / ischemic brain injury, and migraine headaches.SELECTED DRAWING: Figure 1

The invention relates to the technical field of medical equipment, in particular to an intermittent high-oxygen system. The intermittent hyperoxia system provided by the invention can monitor the oxygen concentration, temperature, humidity, pressure and other environmental parameters in the hyperoxia cabin in real time, has alarm and automatic correction functions, can ensure the safety in the hyperoxia treatment process, and avoids the harm to a testee due to the fact that the parameters exceed a set range. The intermittent hyperoxia system can be used for intermittent hyperoxia intervention in the acute stage of ischemic brain injury and other types of brain injury, can effectively improve the neurological function and reduce the cerebral infarction volume, and has important application value and market prospect.

The invention belongs to the technical field of medical treatment, and discloses application of dehydroequol to treatment of neonatal hypoxic ischemic encephalopathy. The dehydroequol is used for treating the neonatal hypoxic-ischemic encephalopathy, and it is proved that the dehydroequol can reduce the area of cerebral infarction induced by hypoxia and ischemia, relieve encephaledema and inhibit oxidative stress and copper death, and has a treatment effect on neonatal hypoxic-ischemic brain injury. Dehydroequol is a medicine for treating hypoxic ischemic encephalopathy of newborns and has a development prospect.

This invention relates to the field of chemiluminescence detection technology for in vitro diagnostic reagents, specifically to an S100-β chemiluminescence detection kit and its preparation method. It provides a chemiluminescence detection kit for central nervous system-specific proteins using magnetic microparticles. The kit comprises: S100-β calibrator, S100-β monoclonal antibody conjugated with carboxyl magnetic beads, S100-β monoclonal antibody labeled with alkaline phosphatase, AMPPD chemiluminescence substrate solution acted upon by alkaline phosphatase, and concentrated washing buffer. This kit achieves the following: no sample pretreatment required, easy operation, high automation, high sensitivity, automatic result output in 16 minutes, good stability of calibrator and enzyme label, and low cost. It can meet the clinical needs for auxiliary diagnosis and treatment of acute ischemic brain injury.

The present application relates to a kind of cytidine choline dextrohydrotalcid derivatives and its preparation method and application, belong to biological medicine technical field.The present application is aimed at solving the technical problems of low blood-brain barrier penetration rate and limited treatment effect of existing edaravone dextrohydrotalcid compound preparation.The present application prepares a dextrohydrotalcid derivative (C-B) with boronic acid structure, then it is compounded with cytidine choline in specific pH buffer system, and forms cytidine choline dextrohydrotalcid derivative (C-D-B).The present application can effectively improve the efficiency of drug crossing blood-brain barrier by using the dynamic covalent characteristics of boronic ester bond and free radical responsiveness.The experimental results show that, compared with existing combination drug, the derivative of the present application can significantly reduce the infarction area of cerebral ischemia model animal, reduce cell damage and active oxygen level, and promote vascular regeneration, and show better treatment effect on ischemic brain injury.

The invention discloses a polypeptide-modified black phosphorus nanosheet composite material for brain targeting and a preparation method thereof, the invention provides the polypeptide-modified black phosphorus nanosheet composite material for brain targeting and the preparation method thereof, and the black phosphorus nanosheet composite material has good drug loading capacity and excellent photo-thermal capacity, and can be applied to brain targeting. The problem of solubility of the resveratrol is solved, and the bioavailability of the resveratrol is improved. The black phosphorus nanosheet composite material disclosed by the invention is modified by ANG polypeptide, penetrates through a blood brain barrier through LRP-1 receptor mediated endocytosis and enters the brain, and has an obvious brain targeting characteristic. Meanwhile, under near-infrared illumination, the blood-brain barrier permeability of the black phosphorus nanosheet composite material can be further improved. The black phosphorus nanosheet composite material disclosed by the invention has a remarkable treatment effect on ischemic brain injury under the conditions of polypeptide modification and near-infrared illumination.

The invention relates to the technical field of polypeptides, in particular to a GALR2 selective polypeptide agonist as well as a preparation method and application thereof. The polypeptide agonist comprises one of polypeptide of an amino acid sequence in a formula I, polypeptide salt of the amino acid sequence in the formula I, polypeptide of an amino acid sequence in a formula II and polypeptide salt of the amino acid sequence in the formula II. Asn-Trp-Thr-X3-X4-Ala-Met-Leu-X1-Leu-X2-Gly-Ala-Gln-NH2, which is represented by a formula I in the specification, is represented by a formula II in the specification, y < 5 >-Trp-Thr-Leu-Asn-Y < 4 >-Al -Leu-Y < 1 >-Leu-Y < 3 >-Gly-Y < 2 >-NH2, which is shown in a formula II; the GALR2 selective polypeptide agonist molecule provided by the invention has high affinity with GALR2 and strong agonist activity, and can be applied to preparation of ischemic brain injury drugs.

The invention relates to mammalian mesenchymal stem cells (MSCs) for use in a method of treatment of a hypoxic-ischemic brain injury (HIBI) event in a human neonate. Particular routes of administration are disclosed. The invention also encompasses the MSCs for use in a method of prevention of the consequences and / or treatment of a neurodevelopmental disability in a neonate which has suffered or is suspected of suffering a HIBI event. A ready to use device for the administering of MSCs to human neonates is also disclosed.

The application provides application of a reagent for detecting N-acetyl-L-cysteine in preparation of an ischemic brain injury diagnosis product, and relates to the technical field of in-vitro detection.The application provides a biomarker N-acetyl-L-cysteine (NAC) for ischemic brain injury diagnosis.ROC curve analysis shows that NAC has good distinguishing ability for ischemic brain injury, and can be used as a potential marker for ischemic brain injury.

The present invention relates to a hydrogel for the treatment of ischemic brain injury and a preparation method thereof. The hydrogel comprises the following raw materials: methacrylated hyaluronic acid, methacrylated gelatin, HA-PPS nanomicelles loaded with curcumin, and sodium alginate microspheres loaded with dendrobium officinale polysaccharide. By combining nanotechnology and intelligent response materials, the present invention uses HA-PPS to load curcumin and sodium alginate microspheres to encapsulate dendrobium officinale polysaccharide, which can more effectively protect the drug activity, protect the drug from crossing the blood-brain barrier, accurately deliver it to the brain injury area, and achieve targeted release of the drug; moreover, the antioxidant and anti-inflammatory effects of curcumin and dendrobium officinale polysaccharide acting together are better, and at the same time, it also has a sustained release function.

A method for identifying the presence or progression of hypoxic ischemic brain injury includes, for each subset of one or more subsets of a three-dimensional medical image of a head of a patient: (i) inputting said each subset into a machine-learning model, (ii) extracting one or more features or feature maps from the machine-learning model, and (iii) constructing, based on the one or more features or feature maps, one of a sequence of vectors. The sequence of vectors is then pooled to obtain a scan-level vector that is used to obtain a score indicating HIBI presence or progression in the patient. For example, the scan-level vector can be inputted into a pre-trained classifier that generates the score based on the scan-level vector. The machine-learning model may be a pre-trained conventional neural network or support vector machine.

The application discloses a compound for treating diseases related to ischemic brain injury, and the compound has the structure shown in the following formula (II). The compound has higher bioavailability, higher distribution concentration in rat plasma and brain tissue, and good effect on ischemic brain injury.

The present application provides a kind of containing sulfuryl bridge physalin compound small physalin S and its preparation method and application, from Physalis pubescens Franch. Isolated and extracted to the new compound small physalin S of physalin, it has the molecular structure of I:Small physalin S of the present application has anti-inflammatory activity, can significantly improve the viability of PC12 cell of hypoxia reperfusion injury, its mechanism of action is related to the expression of inhibiting NLRP3 inflammasome and cell pyroptosis related protein, inhibits the release of inflammatory factors, suggests that small physalin S of the present application can be used as the medicine popularization of treating ischemic brain injury, with good development, application prospect.

The invention provides a tripterygium wilfordii diagnosis and treatment prodrug, a precursor compound as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the tripterygium wilfordii diagnosis and treatment prodrug, hemicyanine fluorescent dye is coupled with a neuroinflammation treatment drug, i.e., cellatrol, and diphenyl phosphinamide is introduced as a response switch, so that the tripterygium wilfordii diagnosis and treatment prodrug can detect ONOO <-> in a neuroinflammation microenvironment and realize targeted release of the cellatrol. The tripterygium wilfordii prodrug for diagnosis and treatment can effectively consume ONOO <-> and realize near-infrared fluorescence imaging in ischemic brain injury, the bioavailability of cellatrol is improved, and the toxicity of the drug is reduced, so that synchronous imaging and treatment are realized. Prodrug with structure as shown in general formula I: # imgabs0 #

The invention discloses a treatment method for regulating hypoxic ischemic brain injury of newborn mice through Prxl2b, and relates to the technical field of hypoxic brain injury. Accurate timing of treatment intervention is achieved, an optimal treatment time window is defined by establishing an oxidative stress mechanical model, it is ensured that supplementation or activation of Prxl2b plays the maximum effect in the stage where oxidative stress is most active and strongest in destructiveness, blindness of empirical drug administration is overcome, and the treatment intervention accuracy is improved. The initial injury volume and the administration delay time are quantified into calculation parameters of a mathematical model, so that the initial load dose and the maintenance dose can be customized for each model mouse, and the treatment intensity is accurately matched with the injury severity; the curative effect is maximized; and the excessive risk is potentially reduced.

The invention relates to the technical field of active polypeptides, and discloses a polypeptide with ASIC1a selective inhibitory activity and application thereof. The amino acid sequence of the polypeptide is EDCIPKWKGCVNRHGDCCEGLECYVRR KSFEVCIPKTPKT, and the amino acid sequence of the polypeptide is shown in the specification. According to the polypeptide with ASIC1a selective inhibitory activity and the application thereof, the polypeptide can specifically inhibit channel current of ASIC1a and can effectively inhibit channel current of ASIC1b, the molecular weight is 4629.40 Da, and compared with a monoclonal antibody with large molecular weight, the polypeptide has good blood-brain barrier penetration rate, does not have remarkable cytotoxicity after being tested by experiments, and can be used for preparing a monoclonal antibody with ASIC1a selective inhibitory activity. The possibility of causing human immune response is low, potential unsafe factors are relatively few, and the compound can be used for preparing neuroprotective drugs for treating ischemic brain injury caused by cerebral arterial thrombosis.

The invention provides application of hyaluronic acid in preparation of a medicine for treating ischemic brain injury. The application finds that hyaluronic acid and a sulfhydrylated derivative thereof can resist ferroptosis, intravenous injection has a treatment effect on ischemic brain injury, traumatic brain injury or neurodegenerative diseases related to ferroptosis, and the hyaluronic acid and the sulfhydrylated derivative thereof have a synergistic effect with other ferroptosis drugs. The discovery provides a new drug research and development direction for research and development of drugs for the diseases.

The invention relates to the technical field of medical image processing, in particular to a cortical thickness atlas analysis system and method for hypoxic ischemic brain injury, and the system comprises a cortical thickness data acquisition unit which generates a cortical thickness thermodynamic diagram with the precision of 0.1 mm through a Laplacian manifold reconstruction algorithm; the fNIRS blood flow data acquisition unit is used for acquiring blood flow signals of 1024 channels and generating a blood flow signal thermodynamic diagram; the multi-center data normalization unit is used for constructing and normalizing multi-center data, and performing Z-score; the part 3 is judged to be abnormal; the sensitive value selection unit is used for superposing the skin layer thinning area and the blood oxygen signal abnormal area on the basis of a topological space intersection mapping technology, and determining a sensitive value 0.9 and an injury responsibility area; and the responsibility area generation unit is used for accurately positioning a responsibility area boundary, constructing a multi-dimensional feature space and generating a responsibility area map, so that high-precision fusion of structural and functional data is realized.

This disclosure relates generally to methods and agents for treating acute neuroinflammatory injury, such as stroke (e.g. ischemic stroke or hemorrhagic stroke), hypoxic-ischemic brain injury, traumatic brain injury, subarachnoid hemorrhage and intracerebral hemorrhage. In particular, the present disclosure relates to the use of CD14 antagonist antibodies for treating acute neuroinflammatory injury.

The invention discloses bacoportulacin 2 targeting an AQP1 target spot after mouse cerebral apoplexy and application of bacoportulacin 2 in cerebral apoplexy intervention, and relates to the technical field of biological medicines, and the action mechanism of the medicine is targeted inhibition of expression and / or functions of aquaporin 1; according to the invention, the application of bacoportulacin 2 is associated with a highly expressed AQP1 target in astrocytes after specific inhibition of cerebral apoplexy, and it is further revealed that the bacoportulacin 2 can play a role by regulating the pathogenicity interaction between AQP1 and downstream protein 4EBP2. The dual-action mechanism of'upstream target inhibition-downstream interaction interference 'provides a new thought and a clear intervention node for developing a collaborative treatment drug aiming at a complex pathological network of ischemic brain injury, and surpasses a traditional strategy of single target inhibition.

Disclosed are 2-aminopyridine derivative compounds for use as inhibitors of nitric oxide synthase (NOS). In particular, the field of the invention relates to 2-aminopyridine derivative compounds for use as inhibitors of neuronal nitric oxide synthase (nNOS), which are formulated as pharmaceutical compositions for treating diseases and disorders associated with nNOS such as Alzheimer's, Parkinson's, and Huntington's diseases, and amyotrophic lateral sclerosis, cerebral palsy, stroke / ischemic brain damage, and migraine headaches.

The application belongs to the technical field of medicine, and particularly relates to pericyte-derived mitochondria-rich extracellular vesicles and application thereof in ischemic brain injury. The extraction method of the extracellular vesicles comprises the following steps: (1) cutting a cerebral cortex part, adding collagenase type II and DNase I for digestion, and then adding a gradient separation liquid to separate pericytes; (2) spreading the pericytes on a culture dish coated with collagen type IV and culturing in a pericyte culture medium; (3) when the cell confluence degree reaches 80% to 90%, the cell culture medium is replaced with a fresh culture medium without exosomes FBS, the cells are subjected to OGD treatment and then reoxygenated for 24 hours, the culture supernatant is collected, and the culture supernatant is centrifuged to obtain the extracellular vesicles. The PC-EVs obtained after OGD stress are found to be capable of protecting the brain from ischemic stroke for the first time, and have important reference significance for researching and treating drugs related to ischemic brain injury.

The invention discloses a small peptide TAT-pxxp for treating ischemic brain injury and application of the small peptide TAT-pxxp, and belongs to the technical field of biomedicine. In order to interfere the direct interaction of TRPV1 and Src, a final small peptide sequence is determined based on a PXXP motif (residues 35-38) in the tail of the N end of a TRPV1 structure and an SH3 structural domain of Src, a TAT cell-penetrating peptide sequence is fused, four glycines are used in the middle for connection, and finally, the interference peptide TAT-pxxp (YGRKKRRQRRR-GGGG-NSKPPPAKPHIFAT) is constructed and can compete with TRPV1 to be combined with Src, so that a downstream inflammation signal channel is inhibited, and the anti-inflammatory effect is improved. Meanwhile, the small peptide can reach the inside of the cell to exert functions.

The invention belongs to the technical field of medicines, and particularly relates to a mitochondria-rich extracellular vesicle derived from periodontal cells and application of the extracellular vesicle in ischemic brain injury. The extraction method of the extracellular vesicles comprises the following steps: (1) chopping a cerebral cortex part, adding type II collagenase and DNaseI for digestion, and then adding a gradient separation medium for separation to obtain pericytes; (2) spreading the periodontal cells on a culture dish coated with IV-type collagen, and culturing in a periodontal cell culture medium; and (3) when the confluence degree of the cells reaches 80%-90%, replacing the cell culture medium with a fresh culture medium without exosome FBS, reoxygenating the cells for 24 hours after OGD treatment, collecting culture supernatant, and centrifuging the culture supernatant to obtain the extracellular vesicles. It is found for the first time that the PC-EVs obtained after OGD stress can protect the brain from ischemic stroke injury, and the PC-EVs have important reference significance for researching related drugs for treating ischemic brain injury.

The present invention relates to a base addition salt of the compound of formula (I) and crystalline forms of the salt, methods for preparing and using the salt, and pharmaceutical compositions containing a therapeutically effective amount of the salt or crystalline form, and their use for treating diseases associated with ischemic brain injury, spinal cord injury, and neurodegenerative diseases. [Formula 1] TIFF2026503034000035.tif75170

An alkali addition salt of a compound represented by formula (I), a salt crystal form, a preparation method and applications thereof, a pharmaceutical composition containing a therapeutically effective amount of the salt or the crystal form, and applications of the pharmaceutical composition in treatment of ischemic brain injury related diseases, spinal cord injury and neurodegenerative diseases. # imgabs0 #

The present application relates to the technical field of active polypeptide, and discloses a polypeptide with ASIC1a selective inhibition activity and application thereof.The amino acid sequence of the polypeptide is EDCIPKWKGCVNRHGDCCEGLECYVRRKSFEVCIPKTPKT.The present application adopts the polypeptide with ASIC1a selective inhibition activity and application thereof, the polypeptide can specifically inhibit the channel current of ASIC1a, can effectively inhibit the channel current of ASIC1b, and has a molecular weight of 4629.40 Da, has a better blood-brain barrier penetration rate compared with a monoclonal antibody with a larger molecular weight, has no significant cytotoxicity through test, has a low possibility of causing human immune response, has relatively less potential unsafe factors, and can be used for preparing a neuroprotective drug for treating ischemic brain injury caused by ischemic stroke.

The invention discloses an application of deoxydan-leaf emodin in preparation of a medicine for treating ischemic brain injury, and belongs to the field of biomedicine. Specifically, the invention relates to an application of deoxydan-leaf emodin in preparation of a medicine for preventing and / or treating ischemic brain injury. According to the invention, a modern analysis method is applied to verify the effect of the deoxydan-leaf emodin on ischemic stroke from multiple dimensions, and the action mechanism of the deoxydan-leaf emodin is analyzed through multi-omics joint analysis, so that a scientific basis is provided for clinical application and deep development of the deoxydan-leaf emodin.